Gemcitabine-related fatal cholestatic hepatitis

Oğuzhan Yildiz\textsuperscript{1,\#}, Melek Karakurt Eryilmaz\textsuperscript{1}, Ali Fuat Gürbüz\textsuperscript{1}, Muzaffer Uğralı\textsuperscript{1}, Sedat Taş Ayçiçek\textsuperscript{2}, Murat Araz\textsuperscript{1}, Mehmet Artaç\textsuperscript{1}

\textsuperscript{1}Department of Oncology, Necmettin Erbakan University, Yunus Emre, Meram/Konya, Türkiye
\textsuperscript{2}Patoloji Anabilim Dalı, Necmettin Erbakan Üniversitesi, Yunus Emre, Konya, Türkiye

Abstract

Introduction. Gemcitabine is used in treatment of such cancers as pancreatic cancer and biliary tract cancer and has been shown to improve progression-free survival in patients with pancreatic cancer when administered as adjuvant chemotherapy. Low-grade elevations in liver enzymes are generally among the known toxicities of gemcitabine. However, it has also been associated with serious and fatal hepatic failure.

Case report. A 71-year-old male patient with pancreatic cancer developed fatal cholestatic hepatitis after six cycles of gemcitabine given as adjuvant chemotherapy.


Discussion. Our case differs from those reported in the literature. In our patient, 10 days after the 6th course of gemcitabine administration, elevated liver enzymes, increased bilirubin, and jaundice were observed. Gemcitabine-induced cholestatic hepatitis was diagnosed because there was no other drug use that could have triggered this reaction.

Keywords: cholestatic hepatitis, gemcitabine, pancreatic cancer
the portal vein in an area of approximately 5 mm. A 5 mm defect in the portal vein wall was continuously sutured with 4/0 prolene.

Pancreaticoduodenectomy was performed in March 2022. In pathological examination, the tumor size was $2 \times 1.7 \times 1.2$ cm. All 15 dissected lymph nodes were reactive. No tumor was detected in the surgical margins. The pathological staging after pancreaticoduodenectomy was determined to be stage 1A disease, according to the American Joint Committee on Cancer (AJCC) TNM Staging of Pancreatic Cancer (8th ed., 2017). Six cycles of gemcitabine were given as adjuvant chemotherapy [1250 mg/m², intravenous (i.v.) infusion on days 1, 8, and 5, repeated every 28 days]. Ten days after the sixth cycle, the patient presented with jaundice. There was an increase in liver enzymes and a significant increase in bilirubin values. His blood test showed the following results: alanine aminotransferase (ALT) 92 IU/L (5–34), aspartate aminotransferase (AST) 127 IU/L (0–55), total bilirubin 21.18 mg/dL (0.2–1.2), direct bilirubin 18.75 mg/dL (0–0.30), alkaline phosphatase (ALP) 720 IU/L (40–129), gamma-glutamyl transpeptidase (GGT) 393 IU/L (0–60), lactate dehydrogenase (LDH) 674 IU/L (135–225), total protein 42.4 g/L (64–83), albumin 21.2 g/L (35–52), white blood cells $11.03 \times 10^9$/L (4.5 to $11.0 \times 10^9$/L), hemoglobin 10 g/dL (12.1–17.2), platelets $81.00 \times 10^3$ u/L (150–400). On abdominal USG, the liver appeared natural, and the biliary tract was normal. Abdominal CT showed ascites, but there was no evidence of peritoneal carcinomatosis or metastases in other organs, including the liver. No thrombus was detected in the hepatic artery or portal vein.

In addition, magnetic resonance cholangiopancreatography (MRCP) was performed. No additional evidence was found to explain the elevated levels of bilirubin and liver enzymes. In ascites sampling, the serum ascites albumin gradient was calculated at 2.4 g/dL. Ascites cytology was reported as benign. Ascites was not caused by malignancy. The patient had no history of exposure to drugs, toxins, alcohol, or other alternative or complementary drugs. Before adjuvant gemcitabine, laboratory data were within the normal reference range. The patient was admitted to the hospital. During the clinical follow-up of the patient, cholestatic enzymes, liver enzymes, and total and direct bilirubin continued to increase (Fig. 1 and 2). Hepatitis A virus-specific immunoglobulin M (IgM) antibody, hepatitis B surface antigen, hepatitis C virus antibody, viral capsid antigen IgM, human immunodeficiency virus (HIV) antibody, and cytomegalovirus antigen were negative. His rheumatological examination was normal, and only antinuclear antibody (ANA) was positive for the immunological markers. In the follow-up, the patient developed hepato-renal syndrome, hepatic encephalopathy, and coagulation disorders after bilirubin elevation. Albumin and terlipressin were given for hepato-renal syndrome. Furthermore, hepatoprotective agents such as ursodeoxycholic acid, liver extracts, and mixed solutions of glycine, glycrrhizin,
and L-cysteine were administered for hepatic encephalopathy.

On October 10, 2022, a biopsy was performed to determine the etiology of acute hepatic failure. The liver biopsy revealed significant inflammatory changes and steatosis findings in the liver (Fig. 3), the appearance of lymphocyte, neutrophil, polymorph, and eosinophil-rich inflammation and lobular

Figure 2. Concentration of gamma-glutamyl transferase (GGT)

Figure 3. Marked inflammatory changes were observed in the liver parenchyma, along with signs of steatosis
Figure 4. The parenchyma exhibits inflammation rich in lymphocytes, neutrophils, polymorphs, and eosinophils, as well as an appearance of lobular cholestasis.

Figure 5. Accumulation of bile segments is concentrated in the ducts and hepatocyte cytoplasm.

Cholestasis in the parenchyma (Fig. 4), and bile pigment deposits in canaliculi and hepatocyte cytoplasm (Fig. 5). As a result, the pathological examination was evaluated as compatible with cholestatic hepatitis and drug-induced hepatocellular damage. Therefore, 1 mg/kg i.v. methylprednisolone was given for 5 days.
The patient’s liver enzymes, total bilirubin, and direct bilirubin values showed a tendency to decrease with methylprednisolone. Despite receiving the best palliative treatment, the patient developed multiple organ failure and died on 22/10/22.

Discussion

Gemcitabine is used as adjuvant therapy in PC patients and significantly prolongs overall survival [3]. Gemcitabine causes adverse reactions such as myelosuppression, nausea, vomiting, fever, fatigue, rashes, anaphylactoid reactions, transient liver enzyme elevation, and flu-like symptoms [4]. Serum amino-transferase elevation is observed in 30–90% of patients receiving gemcitabine. Patients are generally asymptomatic, and transaminase elevation is usually self-limiting. AST and ALT are elevated more than 5 times the normal value in 1–4% of patients. Elevated serum alkaline phosphatase and serum bilirubin are even rarer and are usually mild and transient. However, fatal acute cholestatic liver disease due to gemcitabine has occasionally been reported.

Cholestatic hepatitis is characterized by hepatocellular injury, prominent cholestasis, and portal inflammation [5, 6]. Coeman et al. [7] published a report on a 75-year-old man with non-small cell lung cancer (NSCLC) who developed fatal cholestatic liver failure related to gemcitabine (1000 mg/m²) used as a palliative treatment. A severe cholestatic liver injury was observed, with elevations of total bilirubin and ALP. The patient died of multiple organ failure due to liver failure [7].

Okada et al. [4] published a study on severe cholestatic liver failure associated with gemcitabine monotherapy after pancreaticoduodenectomy for patients with advanced PC.

Kagohashi et al. [8] published a report on a 57-year-old man with large-cell lung cancer receiving gemcitabine 800 mg/m² and vinorelbine 20 mg/m². After this treatment, the patient died from severe hepatic failure, accompanied by an increase in AST, ALT, and total bilirubin.

Some authors have stated that patients with pre-existing liver damage or liver metastases have a dose-dependent increased risk of fatal hepatic failure. Matsuda et al. published a report on a 79-year-old man with PC who received 13 cycles of gemcitabine 800–1000 mg/m². The patient had chronic hepatitis C and type 2 diabetes. Chemoradiotherapy was planned for the patient who could not be operated on. A severe liver injury was observed, with elevations of total bilirubin and ALP. Abdominal CT showed no evidence of liver metastases or obstructive jaundice. Hepatocyte necrosis due to gemcitabine was suspected, and systemic prednisolone (50 mg/day) was given. The patient died of multiple organ failure due to liver failure. An autopsy revealed diffuse hepatic necrosis suggestive of drug-induced hepatocellular injury associated with chronic hepatitis [9].

Samlowski et al. [10] published a case of a patient with metastatic squamous cell carcinoma of the head and neck who developed liver failure 14 days after a single dose of gemcitabine. The patient died of multiple organ failure due to liver failure [10]. Robinson et al. published a report on a 45-year-old woman with metastatic breast cancer receiving carboplatin 450 mg/m² and gemcitabine 1300 mg/m². The patient who received combined chemotherapy developed cholestatic liver disease after chemotherapy. The patient progressed to hepatic coma and died [11].

In addition, Dobbie et al. [12] published a case of gemcitabine-related hepatic veno-occlusive disease in a female with viral hepatitis. The patient received a total of 11 applications of gemcitabine (1000/m²). She was hospitalized one week after the last dose. That patient also progressed to hepatic coma and died [12].

We scored our case using the Naranjo Adverse Drug Reactions Probability Scale. Adverse drug reactions are assigned to a probability category from the total score as follows: definite if the total score is 9 or greater, probable for a score of 5–8, possible for a score of 1–4, and finally unlikely for a score of 0. In our case, we calculated a score of 6. Our case differs from those reported in the literature. In our patient, 10 days after the 6th course of gemcitabine administration, elevated liver enzymes, increased bilirubin, and jaundice were observed. No obstruction was observed in the biliary tract, portal vein, or hepatic artery on USG, CT, or magnetic resonance imaging (MRI). There was also no liver metastasis or peritumoral carcinomatosis. Viral serological markers were negative. The liver biopsy was compatible with cholestatic hepatitis. Gemcitabine-induced cholestatic hepatitis was diagnosed because there the patient received only gemcitabine and no other drug could be related to his worsening condition. Despite palliative support and steroid therapy, the patient died.

In conclusion, it is well known that gemcitabine can cause a mild and transient elevation of serum aminotransferase. However, it should be kept in mind that if jaundice develops in patients receiving gemcitabine, fatal cholestatic liver failure may occur. Therefore, liver enzyme monitoring should be considered during gemcitabine therapy.

Article Information and Declarations

Ethics statement

Written informed consent was obtained from the patient.

https://journals.viamedica.pl/oncology_in_clinical_practice
Author contributions
O.Y.: concept, design, supervision, data collection and/or processing, literature search, writing, critical reviews; M.K.E.: concept, design, supervision, literature search, writing, critical reviews; A.F.G.: supervision, analysis and/or interpretation, critical reviews; M.U.: supervision, analysis and/or interpretation, critical reviews; S.T.A.: supervision, critical reviews; M. Araz: supervision, data collection and/or processing, critical reviews; M. Artaç: supervision, data collection and/or processing, analysis and/or interpretation, critical reviews.

Funding
There is no source of extra-institutional funding in this study.

Acknowledgements
None.

Conflict of interest
Authors declare no conflict of interest.

Supplementary material
None.

References


